drugset / Trial / NCT00302497
EXTEND Protocol for Transplanted Patient to Evaluate Kidney Function
Phase 3
Unknown
50 enrolled
McGill University Health Centre/Research Institute of the McGill University Health Centre
RandomizedSingle-groupOpen-labelTreatment
Summary
The long-term use of calcineurin inhibitors in the maintenance phase after kidney transplantation is associated with typical adverse effects, such as potential contribution to progressive impairment of renal function, hypertension, and metabolic abnormalities. This 15 month study with a safety follow up is undertaken to evaluate the potential benefit of an alternative treatment strategy to the chronic use of CNI. It will establish, through a comparative design, the superior protection of kidney function provided by chronic usage of basiliximab over tacrolimus early post-transplantation using EDC kidneys.
Timeline
- Start
- 2007-04
- Primary completion
- —
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Basiliximab | Monoclonal antibody | — | — |
Indications
No indication recorded.